Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide ...

14 November 2026 · By · Wire by Fusion42

Published

14 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at amylyx.com →

◆ Verified

Fusion42 · 14 November 2026 · Fusion42 review

Amylyx Pharmaceuticals announced that their Phase 3 LUCIDITY trial showed avexitide significantly reduced hypoglycemic event rates by 55% compared to placebo in patients with post-bariatric hypoglycemia, while maintaining a favourable safety profile.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can target post-bariatric hypoglycemia with a new drug class showing strong trial results and good safety, opening treatment options in a previously underserved area. This data invites fast engagement with gastroenterologists and endocrine specialists.

◆ Coverage

1 source · 14 Nov 2026

◆ Related on Wire

◆ Topics

Biotechpost-bariatric-hypoglycemiaphase-3-trialavexitideglp-1-antagonistclinical-safetypb-hypoglycemia